TOLERANZIA AB

TOLERANZIA AB

Toleranzia AB, a biotechnology company, develops and commercializes drugs for the treatment of autoimmune orphan diseases. The company is primarily developing TOL2 drug candidate for treating myasthenia gravis, an autoimmune nerve and muscle disease. It also intends to develop TOL3 drug candidate to treat ANCA vasculitis, an autoimmune blood vessel disease. The company is headquartered in Gothenburg, Sweden.

Toleranzia AB_logo

Industry:
Company

Founded:
12/20/2011

Address:
Erik Dahlbergsgatan 11A, Gothenburg, Sweden Zipcode 411 26

Country:
Sweden

Phone:
46 7 63 19 98 98

Market Cap:
60.87M
Total Revenue:
12.99M
Total Assets:
72.58M
Total Cash:
43.15M

CEO: Charlotte Fribert


Key Executives
Name Title Pay Year Born
Ms. Charlotte Fribert Chief Exec. Officer N/A 1967(53 years old)
Mr. David Wahlund Chief Financial Officer N/A 1980(40 years old)
Mr. Björn Löwenadler Chief Bus. Officer N/A 1952(68 years old)
Mr. Vidar Wendel-Hansen Chief Medical Officer N/A 1959(61 years old)



Financial & Stock
Company's stock symbol is TOL.ST. Lastest price : 1.1200. Total volume :132.07k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.toleranzia.com

  • Host name: uke.oderland.com
  • IP address: 91.201.61.217
  • Location: Sweden
  • Latitude: 59.3247
  • Longitude: 18.056
  • Timezone: Europe/Stockholm

Loading ...
Loading ...


More informations about "Toleranzia AB" on Search Engine

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com About Toleranzia Toleranzia develops drugs that use the immune system’s own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or greatly alleviate the disease and not, like current treatments, only reduce the symptoms.

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Börsplus – Toleranzia: Intressant för den risktolerante, November 2019 BioStock – …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Toleranzia AB’s shares are traded under the short name TOL. Share capital. The share …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Toleranzia’s offices and laboratories are located in “the Biotech Center” in …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Toleranzia’s drug development is founded on the company’s tolerance technology, which …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Charlotte Fribert. Chief Executive Officer, CEO. Charlotte Fribert, born in 1967, studied …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Toleranzia is enthusiastic about the possibility of collaborating with external industrial and …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Toleranzia AB offentliggör prospekt i samband med en 100 procent säkerställd …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Pipeline. Toleranzia’s tolerogens are highly flexible – the disease-specific proteins may …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Charlotte Fribert, CEO, will present Toleranzia at Sedermeradagen Göteborg, taking place …

Harnessing the power of the immune system | Toleranzia AB

Toleranzia.com Reports - Harnessing the power of the immune system | Toleranzia AB

Tämjer kraften i immunsystemet | Toleranzia AB

Toleranzia.se Toleranzia AB publicerar årsredovisning för räkenskapsåret 2020. Toleranzia AB publicerar idag årsredovisning med tillhörande revisionsberättelse avseende räkenskapsåret 2020. Årsredovisningen finns tillgänglig via bolagets... [Läs mer]

Board of Directors - Toleranzia AB

Toleranzia.com Toleranzia AB. Arvid Wallgrens backe 20, 8th floor SE-413 46 Göteborg, Sweden. More contact info

Toleranzia AB - Crunchbase Company Profile & Funding

Crunchbase.com Toleranzia develops drugs that utilize the immune system's own intrinsic power to treat autoimmune orphan diseases. The drugs, which target the disease cause, can cure or greatly alleviate the disease and not just reduce the symptoms that current treatments do. The company's drug candidate, TOL2, is developed for the autoimmune nerve and

TOLERANZIA AB Share Price - TOL Share Price

Stockopedia.com Toleranzia AB is a Sweden-based company engaged in the development of a platform technology for treatment of autoimmune diseases. The Company's main project is aimed against an autoimmune nerve-muscle disease and myasthenia gravis.

Double recognition of Toleranzia AB - Toleranzia

Toleranzia.se Toleranzia AB is an R&D company that has developed a patent protected concept which can be used to treat several autoimmune diseases. The treatment acts on the root cause of the disease and does not only treat the symptoms.

Toleranzia AB - IPOhub

Ipohub.io Toleranzia AB is a pharmaceutical company based in Sweden. The company's drug candidate, TOL2, is being developed for the treatment of the autoimmune neuromuscular disease myasthenia gravis, an …

Toleranzia AB (TOLE) Financial Ratios - Investing.com

Investing.com This TOLE page provides a table containing critical financial ratios such as P/E Ratio, EPS, ROI, and others.

Toleranzia AB — News — GU Ventures

Guventures.com Toleranzia AB (”Toleranzia” eller ”Bolaget”) meddelar att den kritiskt viktiga Master Cell-banken (MCB) som krävs för tillverkning av TOL2 för kliniskt bruk är färdigutvecklad.

Toleranzia AB - Company Profile and News - Bloomberg Markets

Bloomberg.com Company profile page for Toleranzia AB including stock price, company news, press releases, executives, board members, and contact information

TOL:FN Stockholm Stock Quote - Toleranzia AB - Bloomberg

Bloomberg.com Toleranzia AB is a pharmaceutical company. The Company focuses on producing drugs that target autoimmune diseases.

TOL Stock Price | Toleranzia AB Stock Quote (Sweden)

Marketwatch.com Toleranzia AB is a biotechnology company. It engages in the research and development of drugs that utilize the immune system power to treat autoimmune diseases.

Toleranzia AB (TOL.ST) Stock Price, News, Quote & History

Finance.yahoo.com Find the latest Toleranzia AB (TOL.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.

Toleranzia AB - Pharmaceuticals & Healthcare - Deals and

Marketresearchreports.com Mar 15, 2018 · Toleranzia AB (Toleranzia) is a developer of platform technology for the treatment of autoimmune diseases. The company develops and offers products and technologies including Re-Tolerogen for the treatment of autoimmune diseases.

Toleranzia AB - Company Profile - BCIQ

Bciq.biocentury.com Jun 09, 2014 · Toleranzia AB.....company is developing for several indications, including MS, rheumatoid arthritis (RA) and Type I diabetes. Toleranzia.....intranasal delivery of the peptides. The company did not return calls. According to its website, Toleranzia 's...

TLZAF: Dividend Date & History for Toleranzia AB

Dividend.com TLZAF's dividend yield, history, payout ratio, proprietary DARS™ rating & much more! Dividend.com: The #1 Source For Dividend Investing.

Toleranzia AB informerar om teckningsoptioner av serie TO2

Guventures.com May 15, 2020 · Toleranzia AB (556877-2866) är ett svenskt bioteknikföretag som är noterat på Spotlight Stock Market. Bolaget utvecklar läkemedel som utnyttjar immunförsvarets egen kraft för behandling av autoimmuna orphan-sjukdomar. Läkemedlen, som riktar sig mot sjukdomsorsaken, kan lindra eller bota sjukdomen och inte, som nuvarande behandlingar ...

Toleranzia AB | LinkedIn

Linkedin.com Toleranzia AB är ett svenskt bioteknikföretag som är noterat på AktieTorget. Bolaget utvecklar läkemedel som utnyttjar immunförsvarets egen kraft för behandling av autoimmuna sjukdomar.

Toleranzia AB beslutar om en fullt garanterad

Guventures.com Styrelsen i Toleranzia AB (”Toleranzia” eller ”Bolaget”) har idag den 21 augusti 2020 beslutat, med stöd av bemyndigande från årsstämman den 12 juni 2020, om en nyemission av aktier och teckningsoptioner (units) med företrädesrätt för Bolagets befintliga aktieägare (”Företrädesemissionen”).

Maria Fernandez - Programme Director - Toleranzia AB

Se.linkedin.com Toleranzia AB 5 år 2 månader Programme Director Toleranzia AB feb 2018 –nu 3 år 2 månader. Gothenburg, Sweden Management of preclinical development projects. Senior Research Scientist / Project Manager Toleranzia AB feb 2016 – jan 2018 2 år ...

Scaling up the Value with Toleraniza - Testa Center

Testacenter.com Aug 06, 2019 · Toleranzia develops bio-pharmaceticals that utilize the immune system’s own intrinsic power to treat orphan autoimmune diseases. These drugs target the cause of the disease to cure or greatly alleviate the disorder, unlike currently available treatments that only reduce the symptoms.

John Grünberg - Scientific Researcher - Toleranzia AB

Se.linkedin.com Senior Scientific Researcher på Toleranzia AB Göteborg, Sverige 235 kontakter. Gå med för att skapa kontakt Toleranzia AB. University of Gothenburg. Företagswebbplats. Anmäl profilen Aktivitet Surgeon in London performing remote operation on a banana in California using 5G! ...

Toleranzia AB erhåller viktigt finansiellt stöd från

Guventures.com Mar 26, 2020 · Toleranzia AB (”Toleranzia” eller ”Bolaget”) meddelar idag att Bolagets ansökning med projekttiteln ”TOL3: Ett nytt läkemedel mot den autoimmuna sjukdomen ANCA vaskulit” har beviljats ett mycket värdefullt bidrag om 1 992 648 kronor från Vinnova inom utlysningen "Innovationsprojekt i …

Charlotte Fribert, Toleranzia AB: Profile and Biography

Bloomberg.com Toleranzia AB is a pharmaceutical company. The Company focuses on producing drugs that target autoimmune diseases. SECTOR. Health Care. INDUSTRY. Health Care. SUB …

Board of directors - IRLAB

Irlab.se Other ongoing assignments: Board member in Kulturtuben AB, Kulturlådan AB, Kulturpåsen AB, Toleranzia AB and Gypius AB. Deputy board member RolfAllan design AB. Shareholding: 73,510 Class A shares, 5,661 Class B shares and 5,009 warrants that is equivalent to 25,045 Class A shares, directly and through legal entities.

Toleranzia AB har godkänts för notering på Nasdaq First

Guventures.com Sep 30, 2020 · Nasdaq Stockholm AB har idag godkänt Toleranzia AB:s (”Toleranzia” eller ”Bolaget”) ansökan om upptagande till handel av Bolagets aktier och teckningsoptioner av serie TO3 på Nasdaq First North Growth Market (”Nasdaq First North”). Första dag för handel på Nasdaq First North är fastställd till den 1

About Us | Oncorena

Oncorena.com CEO of GU Ventures and chair of GOKAP. Expert at building new companies. Experienced board member in the life science sector including Alzinova AB, Cellink AB, Cereno Scientific AB, Metabogen AB, OnDosis AB, Ortoma AB, PExA AB and Toleranzia AB.

TOLERANZIA AB (0EH.F) Precio de las acciones, noticias

Es-us.finanzas.yahoo.com Encuentra la cotización más reciente, historial, noticias y otra información vital de TOLERANZIA AB (0EH.F) para ayudarte con tus inversiones e intercambios.

Side Airbag Cover Market Report, Forecast 2020 – 2027

Mccourier.com Uncategorized Side Airbag Cover Market Report, Forecast 2020 – 2027, Upcoming Trend Analysis and Key Players – Toleranzia AB , UCB S.A. The global market was value at Million in 2019 and is expected to reach Million by 2027; growing at a CAGR from 2020 to 2027.

Perfil y datos de la empresa de TOLERANZIA AB (0EH.F)

Es-us.finanzas.yahoo.com Conoce el perfil de la compañía TOLERANZIA AB (0EH.F) como el resumen financiero, información sobre la industria y el sector, la cantidad de empleados, la gestión corporativa, los miembros ejecutivos clave y sus compensaciones.

Toleranzia - Overview, News & Competitors | ZoomInfo.com

Zoominfo.com Toleranzia is a company based in Sweden andits vision is to provide new medicines to treat and cure patients with autoimmune diseases. Toleranzia develops drugs that utilize the immune systems own intrinsic power to treat autoimmune orphan diseases.

Orphan Drug Designation granted by FDA - Toleranzia

Toleranzia.se The approval from the FDA is a great acknowledgement of Toleranzia and of its technology platform, says Toleranzias Executive Chairman of the Board Elisabet Litsmark Nordenstam. ... Toleranzia AB. Arvid Wallgrens backe 20, 8 trappor 413 46 Göteborg. Mer kontaktinfo

Toleranzia AB Consensus Estimates (TOLE) - Investing.com

Investing.com Our Toleranzia AB consensus estimates page is based on consensus analyst forecast, covering public companies earnings per share and revenue. You'll be provided with Toleranzia AB overall consensus ...

Nasdaq Stockholm AB: Listing of Toleranzia AB, on Nasdaq

Finanznachrichten.de Sep 29, 2020 · Nasdaq Stockholm AB has assessed that Toleranzia AB, company registration number 556877-2866, fulfills Nasdaq First North Growth Market's listing requirements. Provided that Toleranzia AB…

Kristian S. - Member of the Board - Toleranzia AB | LinkedIn

Se.linkedin.com Member of the Board, Toleranzia AB Södertälje, Sverige Fler än 500 kontakter. Gå med för att skapa kontakt Toleranzia AB. Swedish University of Agricultural Sciences. Anmäl profilen Aktivitet Pioneering research results for Kancera's Fractalkine blockers may pave the way for new treatment for ovarian cancer: https://lnkd.in/dnAFp_9 ...

Últimas noticias y titulares de TOLERANZIA AB (0EH.F)

Es-us.finanzas.yahoo.com Obtén las últimas TOLERANZIA AB (0EH.F) noticias y encabezados de cotizaciones para ayudarte con tus decisiones de operaciones e inversiones.

Maria Charlotte Fribert, Chief Executive Officer at

Relationshipscience.com Toleranzia AB engages in the research and development for treatment of autoimmune diseases. Its study is geared towards the cure of myasthenia gravis. The product is also evaluated to treat type-1 diabetes, rheumatoid arthritis and multiple sclerosis. The company was founded on December 19, 2011 and is headquartered in Gothenburg, Sweden.

Toleranzia AB (via Public) / BioStock intervju

Publicnow.com Mar 12, 2021 · Toleranzia AB. 12/09/2020 | Press release | Distributed by Public on 12/10/2020 02:29. BioStock intervju – Toleranzias erfarna styrelseledamot om bolagets potential. 9 december - 2020 BioStock publicerade den 9 december 2020 en intervju med Toleranzias styrelseledamot Maarten Kraan, som återges nedan i sin helhet.

Toleranzia AB (0EH.F) - Yahoo

Es-us.finanzas.yahoo.com Obtén las últimas TOLERANZIA AB (0EH.F) noticias y encabezados de cotizaciones para ayudarte con tus decisiones de operaciones e inversiones.

Björn Löwenadler - Biography

Marketscreener.com Currently, Björn Löwenadler is Chief Business Officer for Toleranzia AB. He is also on the board of Agrisera AB and Adjuvare AB. In his past career he occupied the position of Head-Discovery Research...

Jan-Olof Andersson - Research Scientist - Toleranzia AB

Linkedin.com Toleranzia AB. apr 2012 – nu 7 år 7 månader. Gothenburg. Research Scientist MIVAC Development AB. aug 2009 – mar 2012 2 år 8 månader. Research Scientist Universityof Gothenburg, Clinical ...

A Sensitive Method for Detecting Peptide-specific CD4+ T

Ncbi.nlm.nih.gov Oct 24, 2017 · (4)Toleranzia AB, Gothenburg, Sweden. Myasthenia gravis (MG) is an autoimmune neurological disorder typified by skeletal muscle fatigue and most often production of autoantibodies against the nicotinic acetylcholine receptor (AChR).

Antigen Specific Immune Tolerance Digital Summit – Home

As-immunetolerance.com The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brought together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. With momentum building for antigen specific immunotherapies, ASIT 2021 was the only antigen-specific summit offering thought-leading content to ...

AtrimusRx AB | LinkedIn

Linkedin.com AtrimusRx AB Pharmaceuticals Stockholm, Stockholm County 236 followers Reliable supplier of shortage and unlicensed medicines.